[go: up one dir, main page]

SG11201403377QA - Glucagon analogues - Google Patents

Glucagon analogues

Info

Publication number
SG11201403377QA
SG11201403377QA SG11201403377QA SG11201403377QA SG11201403377QA SG 11201403377Q A SG11201403377Q A SG 11201403377QA SG 11201403377Q A SG11201403377Q A SG 11201403377QA SG 11201403377Q A SG11201403377Q A SG 11201403377QA SG 11201403377Q A SG11201403377Q A SG 11201403377QA
Authority
SG
Singapore
Prior art keywords
glucagon analogues
glucagon
analogues
Prior art date
Application number
SG11201403377QA
Other languages
English (en)
Inventor
Dieter Wolfgang Hamprecht
Jakob Lind Tolborg
Ditte Riber
Original Assignee
Zealand Pharma As
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As, Boehringer Ingelheim Int filed Critical Zealand Pharma As
Publication of SG11201403377QA publication Critical patent/SG11201403377QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201403377QA 2011-12-23 2012-12-19 Glucagon analogues SG11201403377QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579888P 2011-12-23 2011-12-23
PCT/EP2012/076137 WO2013092703A2 (en) 2011-12-23 2012-12-19 Glucagon analogues

Publications (1)

Publication Number Publication Date
SG11201403377QA true SG11201403377QA (en) 2014-07-30

Family

ID=47594620

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201403377QA SG11201403377QA (en) 2011-12-23 2012-12-19 Glucagon analogues

Country Status (20)

Country Link
US (2) US20130316941A1 (es)
EP (1) EP2793931A2 (es)
JP (1) JP2015502380A (es)
KR (1) KR20140114845A (es)
CN (1) CN104144696A (es)
AP (2) AP2014007797A0 (es)
AU (1) AU2012357739A1 (es)
BR (1) BR112014015681A2 (es)
CA (1) CA2858949A1 (es)
EA (1) EA201490982A1 (es)
HK (1) HK1200369A1 (es)
IL (1) IL232800A0 (es)
IN (1) IN2014CN04401A (es)
MA (1) MA35864B1 (es)
MX (1) MX2014007120A (es)
PE (1) PE20142113A1 (es)
PH (1) PH12014501336A1 (es)
SG (1) SG11201403377QA (es)
TN (1) TN2014000224A1 (es)
WO (1) WO2013092703A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
IN2014MN02304A (es) 2012-05-03 2015-08-07 Zealand Pharma As
EP2664374A1 (en) * 2012-05-15 2013-11-20 F. Hoffmann-La Roche AG Lysin-glutamic acid dipeptide derivatives
CN109456400A (zh) 2012-07-23 2019-03-12 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
GB201315335D0 (en) * 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
RS57632B1 (sr) * 2013-10-17 2018-11-30 Zealand Pharma As Acilovani analozi glukagona
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
JP2017503474A (ja) 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ グルカゴン−glp−1−gipトリプルアゴニスト化合物
CN105849122B (zh) 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽-4(exendin-4)胜肽類似物
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625670A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Gip促效劑化合物及方法
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
MX376200B (es) 2015-02-17 2025-03-07 Amphastar Pharmaceuticals Inc Formulacion en polvo nasal para el tratamiento de hipoglicemia.
PE20180497A1 (es) 2015-03-18 2018-03-09 Zealand Pharma As Analogos de amilina
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
US11179444B2 (en) 2016-06-09 2021-11-23 Amidebio, Llc Glucagon analogs and methods of use thereof
MA45843B1 (fr) 2016-08-05 2021-06-30 Boehringer Ingelheim Int Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
EP3551651B1 (en) * 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CN116854804A (zh) * 2017-08-16 2023-10-10 东亚St株式会社 酰化胃泌酸调节素肽类似物
JP7150032B2 (ja) 2018-02-02 2022-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンo-アシルトランスフェラーゼ(goat)阻害薬として使用するためのヘテロシクリル置換オキサジアゾロピリジン誘導体
EP3746449B1 (en) 2018-02-02 2022-03-30 Boehringer Ingelheim International GmbH Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CN111655700B (zh) 2018-02-02 2023-07-18 勃林格殷格翰国际有限公司 作为饥饿素o-酰基转移酶(goat)抑制剂的噁二唑并吡啶衍生物
JP7083397B2 (ja) 2018-02-02 2022-06-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンo-アシルトランスフェラーゼ(goat)阻害剤として使用するためのトリアゾロピリミジン誘導体
CN111349155B (zh) * 2018-12-24 2022-04-05 浙江和泽医药科技股份有限公司 一种胰高血糖素类似物及其制备方法和用途
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
PH12022551101A1 (en) 2019-11-11 2023-11-13 Boehringer Ingelheim Int Npy2 receptor agonists
ES2984466T3 (es) 2020-05-22 2024-10-29 Boehringer Ingelheim Int Procedimiento de fabricación de 7-amino-5-metil-[1,2,5]oxadiazolo[3,4-b]piridín-carboxilato de alquilo
CN115916789B (zh) 2020-05-22 2025-06-27 勃林格殷格翰国际有限公司 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法
CN113278060B (zh) * 2020-05-29 2022-03-25 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0929567T3 (da) 1996-09-09 2005-06-27 Zealand Pharma As Forbedret fastfase-peptidsyntese og middel til anvendelse af en sådan syntese
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
PL1891105T3 (pl) 2005-06-13 2012-09-28 Imperial Innovations Ltd Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe
WO2007100535A2 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation グルカゴン/glp−1受容体コアゴニスト
ATE520714T1 (de) 2007-06-15 2011-09-15 Zealand Pharma As Glucagonanaloga
EP2307037A4 (en) 2008-06-17 2011-08-03 Univ Indiana Res & Tech Corp GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS
CA2728284C (en) 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
PL2370462T3 (pl) * 2008-12-15 2015-01-30 Zealand Pharma As Analogi glukagonu
US9156901B2 (en) * 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
NZ601167A (en) * 2010-01-20 2014-12-24 Zealand Pharma As Treatment of cardiac conditions
UY33462A (es) * 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon

Also Published As

Publication number Publication date
AP2014007797A0 (en) 2014-07-31
PH12014501336A1 (en) 2014-09-15
HK1200369A1 (en) 2015-10-09
WO2013092703A3 (en) 2013-11-14
BR112014015681A2 (pt) 2019-09-24
KR20140114845A (ko) 2014-09-29
WO2013092703A2 (en) 2013-06-27
US20130316941A1 (en) 2013-11-28
IN2014CN04401A (es) 2015-09-04
US20160347813A1 (en) 2016-12-01
IL232800A0 (en) 2014-07-31
JP2015502380A (ja) 2015-01-22
EP2793931A2 (en) 2014-10-29
TN2014000224A1 (en) 2015-09-30
MX2014007120A (es) 2015-03-05
AP2014007774A0 (en) 2014-07-31
EA201490982A1 (ru) 2015-01-30
MA35864B1 (fr) 2014-12-01
CN104144696A (zh) 2014-11-12
AU2012357739A1 (en) 2014-07-03
PE20142113A1 (es) 2014-12-03
CA2858949A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
IL232800A0 (en) Glucagon analog
ZA201702364B (en) Glucagon analogues
IL231199A0 (en) New analogs of glucagon
AP3286A (en) Glucagon analogues
IL237518A0 (en) Glucagon analog
AP2013006671A0 (en) Glucagon analogues
ZA201306514B (en) Novel glucagon analogues
ZA201206838B (en) Novel glucagon analogues
DK3798230T3 (en) Terapeutiske antistoffer
DK2691417T4 (en) Antistof fc-varianter
ZA201309626B (en) Glucagon/glp-1 reeptor co-agonists
EP2715659A4 (en) ABOUT FEED
EP2662268A4 (en) CAP MOUNTING STRUCTURE
AP2014007621A0 (en) 2-Thiopyrimidinones
EP2695208A4 (en) MICRO-THERMOCOUPLE
DK2770906T3 (en) Applanationstonometer
ZA201403228B (en) Heterocyclypyri(mi)dinylpyrazole
EP2751367A4 (en) LADDER
SG11201402471SA (en) Photocatalyst-supporting structure
CL2014001638A1 (es) Analogos de glucagon
CO7061032A2 (es) Análogos de glucagón
AU4540P (en) BUNNAN Baloskion tetraphyllum
AU5026P (en) Goldstrike Agapanthus inapertus
AU5171P (en) Sunparamiho Mandevilla xamabilis
AU5031P (en) BESYS Beschorneria yuccoides